The FDA has granted a fast track designation to rezpegaldesleukin for treating patients aged 12 years and older with moderate ...

Citius Oncology, Inc. ("Citius Oncology" or the "Company") , a specialty biopharmaceutical company focused on the development and commercialization of novel targeted oncology therapies, today reported ...

Oli Welsh is senior editor, U.K., providing news, analysis, and criticism of film, TV, and games. He has been covering the business & culture of video games for two decades. While it may seem an ...

Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has announced significant findings about ATI-2138, a novel investigational drug ...

Medicenna's long-acting IL-2 Superkine, MDNA11, is a next-generation IL-2 with superior affinity toward CD122 (IL-2 receptor beta) and no CD25 (IL-2 receptor alpha) binding, thereby preferentially ...

(NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for ...

Aclaris Therapeutics (ACRS) announced the availability of a new publication describing properties of Aclaris Therapeutics’ ATI-2138, a novel ...

Division of Rheumatology, Department of Medicine, Washington University School of Medicine, St Louis, United States Siteman Cancer Center, Washington University School of Medicine, St Louis, United ...

BTIG analysts upheld their Buy rating and $15.00 price target for Coya Therapeutics (NASDAQ:COYA), following recent clinical trial data. The stock, currently trading at $7.11, has shown strong ...

Anti-CD19 chimeric antigen receptor (CD19-CAR)-engineered T cells are approved therapeutics for malignancies. The impact of the hinge domain (HD) and the transmembrane domain (TMD) between the ...

In the article that accompanies this editorial, 16 the authors report clinical outcomes from the Japanese phase III JBCRG-M06/EMERALD trial, which compared first-line eribulin plus dual human ...